Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Research Synthesis Methods|June 10, 2015
Graphical displays for meta-analysis: An overview with suggestions for practiceJudith Anzures-Cabrera, Julian P T Higgins
International Journal of Clinical Pharmacology and Therapeutics|March 30, 2012
No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30)Annie Young, Judith Anzures-Cabrera, Michael Derks
Statistics in Medicine|August 10, 2011
Expressing findings from meta-analyses of continuous outcomes in terms of risksJudith Anzures-Cabrera, Ameet Sarpatwari, Julian Pt Higgins
International Journal of Clinical Pharmacology and Therapeutics|January 30, 2013
In vivo evaluation of drug-drug interactions linked to UGT inhibition: the effect of probenecid on dalcetrapib pharmacokineticsPau Aceves Baldó, Judith Anzures-Cabrera, Darren Bentley
Clinical Drug Investigation|March 4, 2011
Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I studyMichael Derks, Judith Anzures-Cabrera, Lynn Turnbull, et al.
Frontiers in Neuroscience|December 30, 2021
Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor ProgressionHolly Jackson, Judith Anzures-Cabrera, Kirsten I Taylor, et al.
Statistics in Medicine|September 19, 2008
Meta-analysis of skewed data: combining results reported on log-transformed or raw scalesJulian P T Higgins, Ian R White, Judith Anzures-Cabrera
Frontiers in Aging Neuroscience|October 9, 2023
Identifying prodromal symptoms at high specificity for Parkinson's diseaseHolly Jackson, Judith Anzures-Cabrera, Tanya Simuni, et al.
The Cochrane Database of Systematic Reviews|July 13, 2012
WITHDRAWN: Opioids for the palliation of breathlessness in advanced disease and terminal illnessAnne Louise Jennings, Andrew N Davies, Julian P T Higgins, et al.
Clinical Pharmacokinetics|February 13, 2013
Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?Mary Phelan, Judith Anzures-Cabrera, David J Carlile, et al.
Pageof 3